Last updated: February 13, 2026
What is NDC 24478-0109?
The National Drug Code (NDC) 24478-0109 refers to Vestronidase alfa (brand name: Vestra), a recombinant form of the enzyme beta-glucuronidase used to treat Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. Approved by the FDA in September 2017, it addresses a rare lysosomal storage disorder caused by enzyme deficiency leading to accumulation of glycosaminoglycans.
What Are the Current Market Dynamics?
Market Size and Patient Population
- Estimated annual prevalence of MPS VII in the US ranges from 1 to 9 patients per million, depending on the source (8K physicians surveyed).
- Worldwide, the patient base is estimated at fewer than 100 patients, making it a very niche market.
- Current diagnosed cases: roughly 20 to 50 globally, with diagnostic underreporting likely.
Competitive Landscape
- No FDA-approved alternative therapies for MPS VII.
- Enzyme replacement therapies (ERTs) for related MPS types (I, II, VI) exist but have limited applicability to MPS VII.
- Supportive treatments address symptoms but do not replace enzyme deficiency.
Pricing Historical Context
- Vestra's list price: approximately $610,000 per year for a typical adult dose (per Medicare Part B and retail sources).
- Pricing for pediatric patients may be similar, adjusted by weight.
- Commercial insurers often negotiate discounts, but list prices remain the benchmark for market assessment.
Reimbursement and Access
- Reimbursement is generally covered due to FDA approval and the rarity status.
- Prior authorization is common, with payers scrutinizing clinical evidence.
What Are the Price Projections and Market Trends?
Factors Influencing Price Stability
- Rarity and small patient base limit price elasticity.
- High development costs recouped through high per-unit prices.
- No new competing therapies projected within the next five years.
Potential Price Trends
| Year |
Price Projection |
Rationale |
| 2023 |
$610,000 |
Current list price, stable due to no competition. |
| 2024 |
$615,000 |
Slight increase reflecting inflation and supply adjustments. |
| 2025 |
$620,000 |
Continued stable pricing with minor adjustments. |
| 2026 |
$625,000 |
No competitive pressure, prices likely maintained. |
Market Penetration and Sales Volume
- Expected annual sales range from $12 million to $30 million, depending on diagnosed patient numbers.
- Sales are constrained by the very small patient population.
Impact of Biosimilars or Generics
- No biosimilar or generic versions exist or are in development for Vestra.
- Market exclusivity, likely via orphan drug designation, extends until 2027.
- Post-exclusivity, prices may decline if biosimilars are approved; however, current regulatory and technical hurdles limit biosimilar entry in rare enzyme therapies.
What Are the Regulatory and Commercial Risks?
- Regulatory: Potential for label expansion could increase the target patient population, influencing sales volumes.
- Reimbursement: Payer resistance or policy changes could pressure discounts.
- Manufacturing: Complex biologic production may cause supply issues, affecting pricing.
Final Market Outlook Summary
- The high price point will likely remain stable in the near term due to absence of alternatives and small patient base.
- Slight incremental increases are possible, reflecting inflation and cost adjustments.
- Market growth depends on improved diagnosis and potential expansion of approved indications or off-label use.
Key Takeaways
- NDC 24478-0109 (Vestra) targets a very small, poorly diagnosed patient group.
- Current pricing around $610,000 per year is standard for enzyme therapies in ultra-rare conditions.
- No immediate competitors or biosimilars threaten pricing stability in the short term.
- Future price declines are possible post-exclusivity or with regulatory changes, but the trend remains stable until then.
- Sales volumes are limited but predictable, closely aligned with the prevalence of MPS VII.
FAQs
1. How is the pricing of Vestra justified given the small patient population?
Pricing reflects high development and manufacturing costs for biologics, with limited patient volume leading to high per-unit costs. Market exclusivity and lack of competitors also sustain high prices.
2. Are there any upcoming changes that could affect Vestra’s price?
Possible influences include post-expiry biosimilar approvals or new indications expanding the patient population, which could impact pricing and market share.
3. What are the main barriers to biosimilar entry?
Biologic complexity, manufacturing challenges, and regulatory requirements limit biosimilar development for enzyme replacement therapies like Vestra.
4. How do reimbursement policies impact market access?
Coverage depends on payer policies; though generally reimbursed due to FDA approval and orphan status, reimbursement negotiations and prior authorizations may affect patient access.
5. Could innovative therapies replace Vestra in the future?
Gene therapies are being developed for lysosomal storage disorders but are not yet approved for MPS VII. Such advances could alter market dynamics and pricing.
References
- FDA Approval Announcement, 2017
- Pricing Information, CMS, 2023
- Market Size Estimates, Orphanet Reports, 2022
- Biopharma Market Reports, EvaluatePharma, 2023
